Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)

Alvaro Mongui; Diana I. Angel; Gina Gallego; Claudia Reyes; Paola Martinez; Felipe Guhl; Manuel A. Patarroyo

doi:10.1016/j.vaccine.2009.10.034

Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)

Alvaro Mongui, Diana I. Angel, Gina Gallego, Claudia Reyes, Paola Martinez, Felipe Guhl, Manuel A. Patarroyo

urosario

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.

Original language	English (US)
Pages (from-to)	415-421
Number of pages	7
Journal	Vaccine
Volume	28
Issue number	2
DOIs	https://doi.org/10.1016/j.vaccine.2009.10.034
State	Published - Dec 11 2009

All Science Journal Classification (ASJC) codes

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2009.10.034

Cite this

@article{38fda456aa564330b635d9f8d3d56ceb,

title = "Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)",

abstract = "This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.",

author = "Alvaro Mongui and Angel, {Diana I.} and Gina Gallego and Claudia Reyes and Paola Martinez and Felipe Guhl and Patarroyo, {Manuel A.}",

note = "Funding Information: We thank Oswaldo Escobar, Silvana Villareal, Hannia Almonacid and Carolina Lopez for their technical support. We would also like to thank Nora Martinez for reviewing this manuscript. Special gratitude goes to Prof. Manuel Elkin Patarroyo for his invaluable comments and suggestions. This research was supported by President of Colombia's office and the “Instituto Colombiano para el Desarrollo de la Ciencia {\textquoteleft}Francisco Jose de Caldas{\textquoteright} (COLCIENCIAS)” contract RC#528-2008. In memory of Ismael Roldan Torres. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.",

year = "2009",

month = dec,

day = "11",

doi = "10.1016/j.vaccine.2009.10.034",

language = "English (US)",

volume = "28",

pages = "415--421",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)

AU - Mongui, Alvaro

AU - Angel, Diana I.

AU - Gallego, Gina

AU - Reyes, Claudia

AU - Martinez, Paola

AU - Guhl, Felipe

AU - Patarroyo, Manuel A.

N1 - Funding Information: We thank Oswaldo Escobar, Silvana Villareal, Hannia Almonacid and Carolina Lopez for their technical support. We would also like to thank Nora Martinez for reviewing this manuscript. Special gratitude goes to Prof. Manuel Elkin Patarroyo for his invaluable comments and suggestions. This research was supported by President of Colombia's office and the “Instituto Colombiano para el Desarrollo de la Ciencia ‘Francisco Jose de Caldas’ (COLCIENCIAS)” contract RC#528-2008. In memory of Ismael Roldan Torres. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.

PY - 2009/12/11

Y1 - 2009/12/11

N2 - This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.

AB - This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.

UR - http://www.scopus.com/inward/record.url?scp=70649093849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649093849&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.10.034

DO - 10.1016/j.vaccine.2009.10.034

M3 - Article

C2 - 19837093

AN - SCOPUS:70649093849

SN - 0264-410X

VL - 28

SP - 415

EP - 421

JO - Vaccine

JF - Vaccine

IS - 2

ER -

Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this